Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects

Inclusion Criteria: * Subject has had stable moderate to severe plaque psoriasis for at least 6 months * Subject must be considered, in the opinion of the investigator, to be a suitable candidate for treatment with a biologic per regional labeling * Subject has involved body surface area (BSA) ≥ 10%, PASI ≥ 12, and sPGA ≥ 3 at screening and at baseline Exclusion Criteria: * Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis, or other skin conditions at (eg, eczema) that would interfere with study evaluations * Subject has known history of Crohn's disease * Subject has any other significant concurrent medical condition or laboratory abnormalities, as defined in the study protocol * Subject has stopped using certain psoriasis therapies as defined in the study protocol * Subject has previously used any anti-IL-17 biologic therapy